Alcresta has received de novo approval from the FDA to market Relizorb (immobilized lipase), a first-of-its kind digestive enzyme cartridge that hydrolyzes fats in enteral tube feeding formula to mimic normal pancreatic function. Relizorb is intended for use by adults on enteral tube feeding who have trouble breaking down and absorbing fats.
Relizorb utilizes the Company’s proprietary enzyme immobilization technology. The active ingredient is called iLipase, which is the enzyme lipase attached to polymeric carriers. The fat in the feeding formula is broken down to fatty acids and monoglycerides prior to ingestion, allowing for increased fat absorption.
Relizorb was shown to break down 90% of fats in most enteral feeding tube formulas, including long-chain polyunsaturated fatty acids necessary for growth and development (eg, docosahexaenoic acid [DHA], eicosapentaenoic acid [EPA], arachidonic acid [AA]).
The list of compatible enteral tube feed formulas and pumps are listed here.
For more information call (844) 735-4967 or visit Relizorb.com.